What Amylin is
Amylin is an endogenous peptide hormone involved in satiety and post-meal metabolic regulation, and it provides the biology behind amylin-analog drugs.
Amylin is grouped under Fat Loss + GLP-1s / Endogenous / Biology on PeptideFactCheck because people run into amylin when they start looking beyond GLP-1 alone for appetite biology.
The useful starting point is to separate the molecule itself from the internet story around it. People run into amylin when they start looking beyond GLP-1 alone for appetite biology.
Why people keep looking it up
People run into amylin when they start looking beyond GLP-1 alone for appetite biology.
Amylin is an endogenous peptide hormone involved in satiety and post-meal metabolic regulation, and it provides the biology behind amylin-analog drugs.
Amylin tends to stay in the conversation because it touches a familiar public theme: satiety signaling, glucose context, and post-meal regulation. That makes it easy for the claim to travel faster than the evidence.
What the evidence can support right now
Strong human biology relevance with indirect drug-development importance.
Human biology is well established, but the drug story belongs to analogs like pramlintide and investigational successors.
Mechanistic work around satiety and post-prandial signaling is strong.
Why this page carries the current tier: Strong human biology relevance with indirect drug-development importance.
The current seed trail for Amylin is pulling from 2 databases sources and 1 literature source.
Safety, limits, and regulatory context
The native hormone, disease biology, and drug analogs should not be collapsed into one thing.
Amylin is tracked here as endogenous biology rather than an FDA-approved standalone peptide drug.
Editorial boundary: PeptideFactCheck does not publish dosing, cycling, sourcing, injection, or administration instructions for Amylin. The job here is to explain the public claim, the mechanism story, the evidence strength, and the current limits.
Molecular and identifier data
The current PubChem match for Amylin is CID 16132430. That gives the page a source-backed chemistry record rather than a placeholder identifier block.
- PubChem CID
- 16132430
- Formula
- C165H261N51O55S2
- Molecular weight
- 3903.3
- InChIKey
- PLOPBXQQPZYQFA-AXPWDRQUSA-N
Matched synonyms include Amlintide, Amylin (human), Diabetes-associated peptide, 122384-88-7, 106602-62-4, Amlintide [USAN:INN], Insulinoma amyloid peptide, Human islet amyloid peptide.
Open PubChem recordClinical trial snapshot
The current ClinicalTrials.gov intervention query for Amylin returns 103 study records. This does not prove efficacy by itself, but it does show whether the peptide is showing up in a formal trial registry rather than only in forums or vendor copy.
Literature snapshot
The current PubMed query for Amylin returns 5328 results. The articles below are a quick literature surface so the page shows actual papers instead of only generic evidence labels.
Source trail
Each linked source is shown directly so the page can be audited. The page now combines its editorial seed trail with automated official-source enrichment generated on 2026-04-24 from PubChem, ClinicalTrials.gov, PubMed, DailyMed, openFDA label, and Drugs@FDA.